Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.

Nyckelord

Administration; Intravesical

Aged

Aged; 80 and over

Antimetabolites; Antineoplastic/*administration & dosage

Bladder Neoplasms/*drug therapy/pathology

Carcinoma; Transitional Cell/*drug therapy/pathology

Deoxycytidine/administration & dosage/*analogs & derivatives

Drug Administration Schedule

Female

Humans

Male

Middle Aged

Neoplasm Recurrence; Local/*drug therapy

Neoplasm Staging

Research Support; Non-U.S. Gov't

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)